BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 9113247)

  • 21. [Glucocorticoids and risk of osteoporosis. On the problem of equivalent dose of desirable and undesirable effects of various glucocorticoids, exemplified by deflazacort].
    Rotenberger J; Köbberling J
    Med Klin (Munich); 1993 Jul; 88(7):432-7. PubMed ID: 8377721
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of glucocorticoids on the hypothalamic-pituitary-adrenal axis in children and adults.
    Gulliver T; Eid N
    Immunol Allergy Clin North Am; 2005 Aug; 25(3):541-55, vii. PubMed ID: 16054542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Glucocorticoid-induced osteoporosis: recent findings].
    Angeli A; Osella G; Reimondo G; Terzolo M
    Ann Ital Med Int; 2000; 15(1):47-55. PubMed ID: 10842891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucocorticoids in the medical management of Graves' ophthalmopathy.
    Hart RH; Perros P
    Minerva Endocrinol; 2003 Sep; 28(3):223-31. PubMed ID: 14605604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Glucocorticoid therapy in childhood].
    Butenandt O
    Fortschr Med; 1991 Aug; 109(23):455-9. PubMed ID: 1916578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Use of glucocorticoids in rheumatoid arthritis].
    Jacobsen S
    Ugeskr Laeger; 2000 Feb; 162(6):770-2. PubMed ID: 10689949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients.
    Yosipovitch G; Hoon TS; Leok GC
    Arch Dermatol; 2001 Apr; 137(4):477-81. PubMed ID: 11295929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitivity of bone to glucocorticoids.
    Cooper MS
    Clin Sci (Lond); 2004 Aug; 107(2):111-23. PubMed ID: 15113280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study.
    Saviola G; Abdi Ali L; Shams Eddin S; Coppini A; Cavalieri F; Campostrini L; Sacco S; Bucci M; Cirino G; Rossini M
    Rheumatology (Oxford); 2007 Jun; 46(6):994-8. PubMed ID: 17384176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucocorticoids and cardiovascular risk factors.
    Strohmayer EA; Krakoff LR
    Endocrinol Metab Clin North Am; 2011 Jun; 40(2):409-17, ix. PubMed ID: 21565675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comprehensive review of the adverse effects of systemic corticosteroids.
    Poetker DM; Reh DD
    Otolaryngol Clin North Am; 2010 Aug; 43(4):753-68. PubMed ID: 20599080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adrenal suppression and osteoporosis after treatment of nasal polyposis.
    Bonfils P; Halimi P; Malinvaud D
    Acta Otolaryngol; 2006 Dec; 126(11):1195-200. PubMed ID: 17050313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucocorticoid-induced osteoporosis in inflammatory bowel disease.
    Lidofsky S; Smith J
    Med Health R I; 2009 Apr; 92(4):128-30. PubMed ID: 19452756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Active vitamin D3 therapy for gulucocorticoid-induced osteoporosis].
    Nakayama H
    Clin Calcium; 2006 Jul; 16(7):1201-7. PubMed ID: 16816482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucocorticoid-induced osteoporosis.
    Reid IR
    Baillieres Best Pract Res Clin Endocrinol Metab; 2000 Jun; 14(2):279-98. PubMed ID: 11035907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index.
    Schäcke H; Berger M; Rehwinkel H; Asadullah K
    Mol Cell Endocrinol; 2007 Sep; 275(1-2):109-17. PubMed ID: 17630119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary and secondary prophylaxis to the use of inhaled glucocorticoid in primary health care.
    Nielsen BR; Jørgensen NR; Schwarz P
    J Asthma; 2008 Aug; 45(6):519-22. PubMed ID: 18612907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Will we ever have better glucocorticoids?
    Buttgereit F; Bijlsma JWJ; Strehl C
    Clin Immunol; 2018 Jan; 186():64-66. PubMed ID: 28757452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uses, adverse effects of abuse of corticosteroids. Part I.
    Imam AP; Halpern GM
    Allergol Immunopathol (Madr); 1994; 22(6):250-60. PubMed ID: 7892813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Corticotherapy: a useful update].
    Le Jeunne C
    Presse Med; 2012 Apr; 41(4):368-9. PubMed ID: 22366445
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.